Related Experiment Video

Updated: Jun 25, 2026

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets

Jeffrey A Knauf1, James A Fagin

  • 1Department of Medicine and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Current Opinion in Cell Biology
|February 24, 2009
PubMed

Insights

Oncogenic BRAF drives tumor development in melanoma and thyroid cancer by activating the MAPK pathway. Understanding BRAF-induced tumor initiation and therapy resistance is key for developing new cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Constitutive activation of the MAPK pathway, often via BRAF mutations, is crucial in cancer development.
  • The role of MAPK pathway activation is particularly evident in melanoma and thyroid cancers.
  • Oncogenic BRAF signaling is a key driver in these specific cancer types.

Purpose of the Study:

  • To review the mechanisms of tumor initiation and progression driven by oncogenic BRAF in melanoma and thyroid cancer.
  • To explore the biochemical events and determinants of oncogene addiction related to BRAF activation.
  • To discuss the distinct biology of BRAF-driven thyroid cancers and implications for therapy.

Main Methods:

  • Literature review of studies on BRAF mutations and MAPK pathway activation in cancer.
  • Analysis of mechanisms underlying tumor initiation, senescence escape, and cellular growth.
  • Examination of oncogene addiction and determinants of therapy sensitivity and resistance.

Main Results:

  • Oncogenic BRAF mediates tumor development by activating the MAPK pathway, influencing tumor initiation and senescence evasion.
  • BRAF-driven cancers exhibit specific biological characteristics, notably in thyroid cancer, affecting cellular growth and hormone production.
  • Understanding BRAF signaling is critical for identifying therapeutic targets and overcoming resistance.

Conclusions:

  • BRAF mutations are significant drivers of melanoma and thyroid cancer, impacting tumor biology and progression.
  • Insights into BRAF-induced oncogenesis are essential for designing targeted therapies and understanding treatment responses.
  • Further research into BRAF and MAPK pathway interactions is needed to develop effective cancer treatments and address therapy resistance.

More Related Videos

Spontaneous Murine Model of Anaplastic Thyroid Cancer05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...